2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.17 Real-world experience of amivantamab monotherapy in EGFR mutated non-small cell lung cancer

Pdf Summary

This study examines the real-world application of amivantamab monotherapy in treating EGFR-mutated non-small cell lung cancer (NSCLC), particularly for patients who are heavily pretreated or unsuitable for chemotherapy or tyrosine kinase inhibitors (TKIs). The study primarily focuses on patients with classical EGFR mutations, such as exon 19 deletions and exon 21 substitutions, as well as those with exon 20 insertions. The presence of TP53 mutations, which could potentially affect treatment outcomes, was also evaluated.<br /><br />The study collected data from 15 patients at the Houston Methodist Hospital. It measured progression-free survival (PFS), clinical response rates, and treatment-related adverse events. The median PFS was found to be 6.14 months overall. Both classical and exon 20 insertion mutation groups demonstrated a clinical response rate of 40%. Notably, the presence of TP53 mutations did not significantly impact the PFS or clinical response rate, suggesting that amivantamab monotherapy is effective regardless of TP53 status.<br /><br />Side effects were notably manageable, with skin rash, venous thromboembolism, and infusion reactions being the most common. Only one patient experienced a grade 3 infusion reaction, leading to treatment cessation, but no grade 4 or higher toxicities were observed.<br /><br />This research suggests that amivantamab monotherapy could be an effective option for patients who have exhausted other treatment avenues or who cannot tolerate TKIs or chemotherapy. Despite limited sample size, the study highlights promising outcomes comparable to combination therapies but with potentially reduced overlapping toxicities. Further large-scale trials are needed to establish more comprehensive insights, particularly focusing on the treatment’s efficacy against brain metastases.

Asset Subtitle

Nicholas Spetsieris

Keywords

amivantamab monotherapy

EGFR-mutated NSCLC

classical EGFR mutations

exon 20 insertions

TP53 mutations

progression-free survival

clinical response rate

treatment-related adverse events

venous thromboembolism

brain metastases